Literature DB >> 10529076

Role of a third generation calcium antagonist in the management of hypertension.

M Epstein1.   

Abstract

Calcium antagonists are uniquely suitable for managing hypertension by virtue of their efficacy, metabolic neutrality and their ability to countervail counterregulatory adaptive changes, thereby enhancing blood pressure lowering. Recent evidence has accrued underscoring the concept that calcium antagonists are heterogeneous and consist of chemically dissimilar agents. The difference in formulations and pharmacokinetics affect clinical events including the effect on blood pressure, heart rate and the degree with which sympathetic activity is activated. Lacidipine is a new calcium antagonist that is the prototype of the lipophilic dihydropyridines. Of great importance, lacidipine has a slow onset of vasodilator/antihypertensive effect and does not promote an excessive sympathetic drive. These attributes commend its selection as an antihypertensive agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529076     DOI: 10.2165/00003495-199957001-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  44 in total

1.  Safety profile of lacidipine: update from a clinical trials database.

Authors:  L H Lindholm; P Tcherdakoff; A Zanchetti
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  Shanghai trial of nifedipine in the elderly (STONE).

Authors:  L Gong; W Zhang; Y Zhu; J Zhu; D Kong; V Pagé; P Ghadirian; J LeLorier; P Hamet
Journal:  J Hypertens       Date:  1996-10       Impact factor: 4.844

3.  Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule.

Authors:  M G Myers; K D Raemsch
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

4.  Maintained autonomic responses to moderate exercise in hypertensive patients treated with lacidipine.

Authors:  D Lucini; P Strappazzon; F Colombo; A Malliani; M Pagani
Journal:  J Hypertens       Date:  1997-12       Impact factor: 4.844

5.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

Review 6.  Current status of calcium channel blockers.

Authors:  W H Frishman
Journal:  Curr Probl Cardiol       Date:  1994-11       Impact factor: 5.200

7.  Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition.

Authors:  D R Abernethy; J Gutkowska; L M Winterbottom
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

8.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

9.  Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation.

Authors:  D G Bailey; J M Arnold; J R Bend; L T Tran; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

10.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  3 in total

Review 1.  Manidipine: a review of its use in hypertension.

Authors:  S M Cheer; K McClellan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Lacidipine: a review of its use in the management of hypertension.

Authors:  Paul L McCormack; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Results of a 14-Week, Multicenter, Prospective, Randomized, Open-Label, Noninferiority Clinical Trial Comparing the Antihypertensive Effect and Edema Incidence of Lacidipine and Amlodipine in Older Korean Patients with Mild-to-Moderate Hypertension.

Authors:  Jin Oh Na; Hong Seog Seo; Cheol Ung Choi; Hong Euy Lim; Jin Won Kim; Eung Ju Kim; Seong Woo Han; Seung-Woon Rha; Chang Gyu Park; Dong Joo Oh
Journal:  Curr Ther Res Clin Exp       Date:  2013-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.